Breaking News
Hansa Biopharma
About Hansa Biopharma
Hansa Biopharma is an innovative and rapidly growing biopharmaceutical company. Our vision is a world where all patients with rare immunologic diseases can lead long and healthy lives. But we often see that people with rare diseases are relegated to the impossible and left to fend for themselves. That’s not the way forward. We see all patients as equal individuals with individual needs. A point of view that gives us a unique ability to deliver the most inclusive care to everyone. For us the mission is clear – we want to develop lifesaving and life altering therapies to those who need them the most. And ultimately, we can – and will – eliminate rare diseases, one patient at a time.
Hansa Announces Global Pivotal Phase 3 Trial in Anti-GBM Disease
May 30 2023
Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, today announced the first […]
Hansa Biopharma Completes Enrollment in Phase 2 Study of Imlifidase in Guillain-Barré Syndrome (GBS)
March 31 2023
Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, today announced it has […]
Hansa Biopharma Announces Positive Reimbursement in Spain for Idefirix as Desensitization Treatment for Patients in Kidney Transplantation
March 30 2023
Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, has announced that the […]
Matthew Shaulis appointed Chief Commercial Officer and US President of Hansa Biopharma
March 3 2023
Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, announced today that Matthew […]
Hansa Biopharma Announces Reimbursement in Italy for Idefirix as Desensitization Treatment for Highly Sensitized Patients in Kidney Transplantation
December 8 2022
Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, has announced that the […]
Hansa Biopharma Announces Positive Topline Data from a Study in Antibody Mediated Rejection (AMR) Post Kidney Transplantation
November 29 2022
Hansa Biopharma AB, a pioneer in enzyme technology for rare immunological conditions, today announces positive […]
The Scottish Medicines Consortium (SMC) Recommends Use of Hansa Biopharma’s Idefirix® (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients
September 13 2022
Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, […]
Hansa Biopharma and Medison Pharma Announce Positive Reimbursement Decision in Poland for Idefirix® in Highly Sensitized Kidney Transplant Patients
August 23 2022
Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological […]
Hansa Biopharma Announces $70 Million Non-dilutive Product Finance Transaction With NovaQuest to Support Continued Development of the Company's Antibody-cleaving Enzyme Technology Platform
July 19 2022
Hansa Biopharma AB, (Hansa), (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological […]
Hansa Biopharma Announces First Patient Treated in the Post-authorization Efficacy Study (PAES) of Idefirix® (Imlifidase) in Highly Sensitized Kidney Transplant Patients
July 11 2022
Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), pioneer in enzyme technology for rare immunological conditions, […]
NICE Recommends Use of Hansa Biopharma's Idefirix® (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients
June 16 2022
Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), pioneer in enzyme technology for rare immunological conditions, today […]